Verdicts genuinely change. Free email alert the moment PHSRX's does — no target price to set, unlike "Alert" above.
Whether this fund clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Putnam Global Health Care Fund
115 holdings
This fund holds short positions, so exposure is counted gross — long and short both count as exposure rather than netting off, and the weights below therefore sum to 101% of net assets rather than 100%. Shares of the portfolio are shown as shares of that gross exposure.
NON-COMPLIANT 14.97% of portfolio weight is in non-compliant holdings, over the 5% threshold.
0.17% of that is conventional interest-bearing debt, identified from the fund's own filing rather than by screening an issuer. Sukuk are deliberately excluded from this test and are never counted here.
115 holdings, 34 matched (94% of weight). Portfolio as of 2026-05-31, filed 2026-07-27. Source: SEC Form N-PORT.
0.79% of this portfolio’s income is non-permissible — weighted across holdings, computed over 79% of portfolio weight (27 of 115 holdings). The common approach purifies that proportion of income received — dividends — not of the position’s value. We report the ratio; what to do with it is a question for your own scholar.
79.5% compliant 0.0% questionable 14.9% non-compliant 5.7% unscreened
| Holding | Status | Weight | Every methodology, and the debt ratio behind it |
|---|---|---|---|
| LLY Eli Lilly & Co. | COMPLIANT | 13.15% | AAOIFI5.2% Usmani38.6% Dow Jones Islamic6.4% S&P Shariah6.9% MSCI Islamic38.6% MSCI Islamic M-Series6.9% FTSE Shariah38.6% |
| JNJ Johnson & Johnson | COMPLIANT | 8.46% | AAOIFI7.6% Usmani24.4% Dow Jones Islamic10.9% S&P Shariah11.7% MSCI Islamic24.4% MSCI Islamic M-Series11.7% FTSE Shariah24.4% |
| UNH UnitedHealth Group, Inc. | NON_COMPLIANT | 6.93% | AAOIFI20.4% Usmani23.7% Dow Jones Islamic20.4% S&P Shariah18.8% MSCI Islamic23.7% MSCI Islamic M-Series18.8% FTSE Shariah23.7% |
| ABBV AbbVie, Inc. | COMPLIANT | 6.05% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| NVS Novartis AG | COMPLIANT | 5.13% | AAOIFI12.5% Usmani25.9% Dow Jones Islamic11.8% S&P Shariah12.6% MSCI Islamic25.9% MSCI Islamic M-Series12.6% FTSE Shariah25.9% |
| MRK Merck & Co., Inc. | COMPLIANT | 4.88% | AAOIFI14.7% Usmani41.5% Dow Jones Islamic21.8% S&P Shariah20.9% MSCI Islamic41.5% MSCI Islamic M-Series20.9% FTSE Shariah41.5% |
| AZN AstraZeneca plc | COMPLIANT | 4.67% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| TMO Thermo Fisher Scientific, Inc. | COMPLIANT | 4.50% | AAOIFI20.5% Usmani40.3% Dow Jones Islamic23.4% S&P Shariah22.9% MSCI Islamic40.3% MSCI Islamic M-Series22.9% FTSE Shariah40.3% |
| ISRG Intuitive Surgical, Inc. | COMPLIANT | 4.04% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| SNY Sanofi SA | COMPLIANT | 3.23% | AAOIFI20.8% Usmani14.7% Dow Jones Islamic38.1% S&P Shariah38.6% MSCI Islamic14.7% MSCI Islamic M-Series38.6% FTSE Shariah14.7% |
| EW Edwards Lifesciences Corp. | COMPLIANT | 2.80% | AAOIFI1.4% Usmani5.1% Dow Jones Islamic1.5% S&P Shariah1.5% MSCI Islamic5.1% MSCI Islamic M-Series1.5% FTSE Shariah4.3% |
| RO.SW Roche Holding AG | COMPLIANT | 2.79% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| CVS CVS Health Corp. | NON_COMPLIANT | 2.74% | AAOIFI61.7% Usmani30.1% Dow Jones Islamic84.9% S&P Shariah88.7% MSCI Islamic30.1% MSCI Islamic M-Series88.7% FTSE Shariah24.2% |
| GILD Gilead Sciences, Inc. | COMPLIANT | 2.63% | AAOIFI14.4% Usmani53.2% Dow Jones Islamic18.6% S&P Shariah21.4% MSCI Islamic53.2% MSCI Islamic M-Series21.4% FTSE Shariah53.2% |
| MCK McKesson Corp. | COMPLIANT | 2.14% | AAOIFI12.5% Usmani14.9% Dow Jones Islamic14.5% S&P Shariah15.8% MSCI Islamic14.7% MSCI Islamic M-Series15.8% FTSE Shariah12.5% |
| CAH Cardinal Health, Inc. | COMPLIANT | 2.12% | AAOIFI17.8% Usmani17.7% Dow Jones Islamic24.8% S&P Shariah28.7% MSCI Islamic17.4% MSCI Islamic M-Series28.7% FTSE Shariah15.5% |
| VRTX Vertex Pharmaceuticals, Inc. | COMPLIANT | 1.97% | AAOIFI1.6% Usmani7.2% Dow Jones Islamic1.7% S&P Shariah1.7% MSCI Islamic7.2% MSCI Islamic M-Series1.7% FTSE Shariah0.0% |
| NOVO-B.CO Novo Nordisk A/S | COMPLIANT | 1.90% | AAOIFIpass Usmanipass Dow Jones Islamicpass S&P Shariahpass MSCI Islamicpass MSCI Islamic M-Seriespass FTSE Shariahpass |
| BSX Boston Scientific Corp. | COMPLIANT | 1.80% | AAOIFI19.4% Usmani27.9% Dow Jones Islamic10.0% S&P Shariah10.9% MSCI Islamic27.9% MSCI Islamic M-Series10.9% FTSE Shariah27.9% |
| BMY Bristol-Myers Squibb Co. | NON_COMPLIANT | 1.75% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| DXCM Dexcom, Inc. | COMPLIANT | 1.64% | AAOIFI4.1% Usmani21.7% Dow Jones Islamic4.7% S&P Shariah4.0% MSCI Islamic20.9% MSCI Islamic M-Series4.0% FTSE Shariah19.3% |
| Hoya Corp. | UNSCREENED | 1.52% | no in-house ratios for this holding |
| Putnam Short Term Investment Fund | UNSCREENED | 1.35% | no in-house ratios for this holding |
| HCA HCA Healthcare, Inc. | NON_COMPLIANT | 1.18% | AAOIFI57.2% Usmani82.9% Dow Jones Islamic53.5% S&P Shariah56.7% MSCI Islamic81.7% MSCI Islamic M-Series56.7% FTSE Shariah78.1% |
| AMGN Amgen, Inc. | COMPLIANT | 1.11% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| WAT Waters Corp. | COMPLIANT | 1.03% | AAOIFI14.1% Usmani21.2% Dow Jones Islamic21.2% S&P Shariah23.3% MSCI Islamic21.2% MSCI Islamic M-Series23.3% FTSE Shariah19.7% |
| ARGX Argenx SE | COMPLIANT | 0.92% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| GSK GSK plc | COMPLIANT | 0.88% | AAOIFI19.2% Usmani23.6% Dow Jones Islamic10.6% S&P Shariah11.2% MSCI Islamic23.6% MSCI Islamic M-Series11.2% FTSE Shariah23.6% |
| RPRX Royalty Pharma plc | NON_COMPLIANT | 0.85% | AAOIFI24.4% Usmani45.2% Dow Jones Islamic60.3% S&P Shariah67.3% MSCI Islamic45.2% MSCI Islamic M-Series67.3% FTSE Shariah45.2% |
| CHGCY Chugai Pharmaceutical Co. Ltd. | COMPLIANT | 0.83% | AAOIFIpass Usmanifail Dow Jones Islamicpass S&P Shariahpass MSCI Islamicfail MSCI Islamic M-Seriespass FTSE Shariahfail |
| REGN Regeneron Pharmaceuticals, Inc. | COMPLIANT | 0.82% | AAOIFI2.4% Usmani6.5% Dow Jones Islamic3.0% S&P Shariah2.7% MSCI Islamic4.8% MSCI Islamic M-Series2.7% FTSE Shariah4.8% |
| Insmed, Inc. | UNSCREENED | 0.66% | no in-house ratios for this holding |
| UTHR United Therapeutics Corp. | NON_COMPLIANT | 0.60% | AAOIFI0.0% Usmani0.0% Dow Jones Islamic0.0% S&P Shariah0.0% MSCI Islamic0.0% MSCI Islamic M-Series0.0% FTSE Shariah0.0% |
| Xenon Pharmaceuticals, Inc. | UNSCREENED | 0.50% | no in-house ratios for this holding |
| Apogee Therapeutics, Inc. | UNSCREENED | 0.49% | no in-house ratios for this holding |
| ASND Ascendis Pharma A/S | COMPLIANT | 0.48% | AAOIFI— Usmani— Dow Jones Islamic— S&P Shariah— MSCI Islamic— MSCI Islamic M-Series— FTSE Shariah— |
| RYTM Rhythm Pharmaceuticals, Inc. | NON_COMPLIANT | 0.46% | AAOIFI1.6% Usmani25.1% Dow Jones Islamic2.0% S&P Shariah2.5% MSCI Islamic25.1% MSCI Islamic M-Series2.5% FTSE Shariah24.3% |
| Putnam Cash Collateral Pool LLC | UNSCREENED | 0.44% | no in-house ratios for this holding |
| CYTK Cytokinetics, Inc. | NON_COMPLIANT | 0.29% | AAOIFI3.9% Usmani20.7% Dow Jones Islamic5.9% S&P Shariah6.2% MSCI Islamic20.7% MSCI Islamic M-Series6.2% FTSE Shariah14.3% |
| Newamsterdam Pharma Co. NV | UNSCREENED | 0.28% | no in-house ratios for this holding |
| United States of America | NON_COMPLIANT | 0.17% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.04% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.04% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.03% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.03% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.02% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.02% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.02% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.01% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Australian Dollar | UNSCREENED | 0.00% | no in-house ratios for this holding |
| N/A | UNSCREENED | 0.00% | no in-house ratios for this holding |
| EURO | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Swiss Franc | UNSCREENED | 0.00% | no in-house ratios for this holding |
| Danish Krone | UNSCREENED | 0.00% | no in-house ratios for this holding |
The published standards disagree about this fund by 42 points of portfolio weight — 78.3% of it passes AAOIFI, 35.9% passes MSCI Islamic. Which number is yours depends on which standard you follow.
These bars are the financial-ratio result under each standard — debt, receivables and interest income. They do not screen what the business does, so a holding can pass every ratio here and still be questionable or non-compliant on activity. The blended verdict above accounts for both.
ratios pass on 78.3% ratios fail on 5.6% 16.8% not rated under AAOIFI
ratios pass on 44.9% ratios fail on 39.0% 16.8% not rated under Usmani
ratios pass on 64.8% ratios fail on 14.0% 21.9% not rated under Dow Jones Islamic
ratios pass on 69.0% ratios fail on 9.7% 21.9% not rated under S&P Shariah
ratios pass on 35.9% ratios fail on 44.8% 19.9% not rated under MSCI Islamic
ratios pass on 66.9% ratios fail on 11.8% 21.9% not rated under MSCI Islamic M-Series
ratios pass on 42.5% ratios fail on 36.2% 21.9% not rated under FTSE Shariah
33 of 115 listed holdings carry our own per-methodology verdicts (95% of weight). The rest hold a provider verdict with no methodology breakdown, and are counted as rated by none. Of those, 24 (74% of weight) also carry the underlying debt ratio; the rest show a verdict without the figure behind it.
| Non-compliant holding | Weight |
|---|---|
| UNH UnitedHealth Group, Inc. | 6.93% |
| CVS CVS Health Corp. | 2.74% |
| BMY Bristol-Myers Squibb Co. | 1.75% |
| HCA HCA Healthcare, Inc. | 1.18% |
| RPRX Royalty Pharma plc | 0.85% |
| UTHR United Therapeutics Corp. | 0.60% |
| RYTM Rhythm Pharmaceuticals, Inc. | 0.46% |
| CYTK Cytokinetics, Inc. | 0.29% |
| United States of America | 0.17% |
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Putnam Global Health Care Fund (PHSRX) is currently considered not halal (non-compliant), per our own look-through to its filed holdings. See its filed holdings and the weight breakdown below for the reasoning.
HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A holding it cannot cover far enough is reported as unrated rather than counted as a pass.
| Holding | Weight | Verdict |
|---|---|---|
| LLYEli Lilly & Co. | 13.15% | Compliant |
| JNJJohnson & Johnson | 8.46% | Compliant |
| UNHUnitedHealth Group, Inc. | 6.93% | Non-compliant |
| ABBVAbbVie, Inc. | 6.05% | Compliant |
| NVSNovartis AG | 5.13% | Compliant |
| MRKMerck & Co., Inc. | 4.88% | Compliant |
| AZNAstraZeneca plc | 4.67% | Compliant |
| TMOThermo Fisher Scientific, Inc. | 4.50% | Compliant |
| ISRGIntuitive Surgical, Inc. | 4.04% | Compliant |
| SNYSanofi SA | 3.23% | Compliant |
Top 10 of 115 holdings, 61.1% of the fund by weight. Every holding is screened, not only these.
The positions keeping this fund short of 100% compliant by weight.
Verdict history for PHSRX. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
ℹ️ no compliance scan has run for 3 days - this is not a reading of today
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
This fund prices once a day, so its bars carry no intraday high or low — floor-trader pivots are not defined for it.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 59.90 | NEUTRAL |
| Stochastic %K (14) | 100.00 | SELL |
| CCI (20) | 155.82 | SELL |
| Williams %R (14) | 0.00 | SELL |
| MACD (12,26,9) | 0.20 | BUY |
| ROC (10) | 4.63 | BUY |
| Momentum (10) | 2.63 | BUY |
| EMA (10) | 57.94 | BUY |
| SMA (10) | 57.54 | BUY |
| EMA (20) | 57.96 | BUY |
| SMA (20) | 57.86 | BUY |
| EMA (30) | 58.09 | BUY |
| SMA (30) | 58.08 | BUY |
| EMA (50) | 58.13 | BUY |
| SMA (50) | 58.72 | BUY |
| EMA (100) | 57.64 | BUY |
| SMA (100) | 57.77 | BUY |
| EMA (200) | 56.65 | BUY |
| SMA (200) | 56.49 | BUY |
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR reads the fund's filed holdings and screens each one, then reports the result by weight. A fund marketed as Islamic still gets the same look-through as any other.
It is the share of the fund whose holdings HTR cannot cover far enough to rate. It is reported as unrated rather than counted as compliant, because a holding nobody screened should not look like one that passed.
It matters, and it is noted, but it does not replace the look-through. The board's judgement and the holdings screen are shown separately so you can see when they agree and when they do not.
When the fund files new holdings, and on a rolling basis besides. The date on the verdict above is the last time this fund was actually recomputed.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.